IO Frontiers World 2019


Tatjana Kolevska

Dr Tatjana Kolevska

Oncologist, Kaiser Permanente

Dr. Tatjana Kolevska is the Chair of Kaiser Permanente Northern California Oncology and Hematology service covering 4 million members. She oversees the practice of over 120 oncologists and hematologists practicing in 21 hospitals.

She is an Associate Director of the Kaiser Permanente Oncology and Hematology Clinical Trials Program that enrolls over 700 patients per year in clinical trials.

Dr. Kolevska is the Chair of the Northern California Kaiser Permanente Physician Education Program facilitating education for over 9000 physicians from different disciplines. She is an Assistant Professor of Clinical Medicine at the University of California, San Francisco (UCSF) as well.

Prior to moving to California she finished hematology and oncology fellowship at Columbia University in New York. Before she moved to the United States she was a part of the Bone marrow Transplantation Team that introduced this procedure in Croatia and did laboratory research in England in the same area. She finished internal medicine/cardiology residency in Zagreb, Croatia and Medical School/ Masters of Science in Clinical Immunology and Allergy at the University of Zagreb in Croatia.  

  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy